ELEDON PHARMACEUTICALS

Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023

23 Mar 2023 07:00:02 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

08 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Provides Business and Pipeline Updates

09 Jan 2023 07:31:00 By Nasdaq GlobeNewswire

C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

21 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results

14 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

03 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS

24 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Participate in Two Upcoming Conferences

03 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

22 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

06 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences

29 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results

11 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

04 Aug 2022 15:05:03 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation

18 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation

09 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference

02 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

31 May 2022 05:00:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results

12 May 2022 15:01:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

09 May 2022 07:00:02 By Nasdaq GlobeNewswire